Bonfrer JM - Search Results

1

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease.

Zuetenhorst JM, Korse CM, Bonfrer JM, Bakker RH, Taal BG. Zuetenhorst JM, et al. Among authors: bonfrer jm. Br J Cancer. 2004 Jun 1;90(11):2073-9. doi: 10.1038/sj.bjc.6601816. Br J Cancer. 2004. PMID: 15150565 Free PMC article. Clinical Trial.

2

The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma.

Bonfrer JM, Korse CM, Nieweg OE, Rankin EM. Bonfrer JM, et al. Br J Cancer. 1998 Jun;77(12):2210-4. doi: 10.1038/bjc.1998.368. Br J Cancer. 1998. PMID: 9649135 Free PMC article.

3

Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.

Korse CM, Bonfrer JM, Aaronson NK, Hart AA, Taal BG. Korse CM, et al. Among authors: bonfrer jm. Neuroendocrinology. 2009;89(3):296-301. doi: 10.1159/000162876. Epub 2008 Oct 7. Neuroendocrinology. 2009. PMID: 18840995

4

Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.

Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JM. Korse CM, et al. Among authors: bonfrer jm. J Clin Oncol. 2009 Sep 10;27(26):4293-9. doi: 10.1200/JCO.2008.18.7047. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667278

5

Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor.

Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG. Zuetenhorst JM, et al. Among authors: bonfrer jm. Cancer. 2003 Apr 1;97(7):1609-15. doi: 10.1002/cncr.11226. Cancer. 2003. PMID: 12655516 Free article.

6

Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors.

Zuetenhorst JM, Korse CM, Bonfrer JM, Peter E, Lamers CB, Taal BG. Zuetenhorst JM, et al. Among authors: bonfrer jm. Clin Chem. 2004 Sep;50(9):1634-9. doi: 10.1373/clinchem.2004.032151. Epub 2004 Jul 9. Clin Chem. 2004. PMID: 15247155

7

Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer.

Bruning PF, Van Doorn J, Bonfrèr JM, Van Noord PA, Korse CM, Linders TC, Hart AA. Bruning PF, et al. Among authors: bonfrer jm. Int J Cancer. 1995 Jul 28;62(3):266-70. doi: 10.1002/ijc.2910620306. Int J Cancer. 1995. PMID: 7543079

8

Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer.

Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Gallee MP, Hart AA, Müller M, Trimbos JB, Helmerhorst TJ. Gaarenstroom KN, et al. Among authors: bonfrer jm. Cancer. 1994 Oct 15;74(8):2307-13. doi: 10.1002/1097-0142(19941015)74:8<2307::aid-cncr2820740815>3.0.co;2-x. Cancer. 1994. PMID: 7922982

9

Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.

Gaarenstroom KN, Bonfrer JM, Kenter GG, Korse CM, Hart AA, Trimbos JB, Helmerhorst TJ. Gaarenstroom KN, et al. Among authors: bonfrer jm. Cancer. 1995 Sep 1;76(5):807-13. doi: 10.1002/1097-0142(19950901)76:5<807::aid-cncr2820760515>3.0.co;2-m. Cancer. 1995. PMID: 8625184

10

Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.

Bonfrer JM, Gaarenstroom KN, Korse CM, Van Bunningen BN, Kenemans P. Bonfrer JM, et al. Anticancer Res. 1997 May-Jun;17(3C):2329-34. Anticancer Res. 1997. PMID: 9245246

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters